Literature DB >> 25112441

Transplantation: Alemtuzumab induction reduces acute rejection risk.

Peter Sidaway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25112441     DOI： 10.1038/nrneph.2014.143

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  1 in total

1.  Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.

Authors:  Richard Haynes; Paul Harden; Parminder Judge; Lisa Blackwell; Jonathan Emberson; Martin J Landray; Colin Baigent; Peter J Friend
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.